<DOC>
	<DOCNO>NCT03047031</DOCNO>
	<brief_summary>This active surveillance study monitor real world safety nintedanib Indian patient Idiopathic Pulmonary Fibrosis . The safety nintedanib assess clinical trial . Since 20 patient India enrol INPULSIS trial , safety data Indian patient limited . In active surveillance , safety nintedanib IPF patient examine Indian real world set</brief_summary>
	<brief_title>Post Marketing Surveillance Nintedanib Indian Patients With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Patients IPF ( IPFtreatment na√Øve pretreated ) newly prescribe nintedanib accord package insert . Willing able provide inform consent . Patients visit/contact possible planned period active surveillance . Patients take nintedanib participation active surveillance . Patients treat pirfenidone . Patients participate clinical trial IPF registry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>